Abstract
Clinical investigation of novel treatments for glioblastoma has been met with repeated setbacks over the past two decades. Modest, but clinically meaningful, improvement in survival has only been shown for temozolomide 1 Stupp R Mason WP van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352: 987-996 Crossref PubMed Scopus (14754) Google Scholar and tumour-treating fields, 2 Stupp R Taillibert S Kanner A et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017; 318: 2306-2316 Crossref PubMed Scopus (1066) Google Scholar whereas many randomised trials assessing drugs targeted to vascular endothelial growth factor, 3 Gilbert MR Dignam JJ Armstrong TS et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014; 370: 699-708 Crossref PubMed Scopus (1854) Google Scholar , 4 Chinot OL Wick W Mason W et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014; 370: 709-722 Crossref PubMed Scopus (1723) Google Scholar integrins, 5 Stupp R Hegi ME Gorlia T et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071–22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2014; 15: 1100-1108 Summary Full Text Full Text PDF PubMed Scopus (669) Google Scholar and epidermal growth factor receptor (EGFR), 6 Weller M Butowski N Tran DD et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol. 2017; 18: 1373-1385 Summary Full Text Full Text PDF PubMed Scopus (580) Google Scholar showed that such drugs failed to prolong patient survival. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trialOur results suggest that lomustine-temozolomide chemotherapy might improve survival compared with temozolomide standard therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter. The findings should be interpreted with caution, owing to the small size of the trial. Full-Text PDF
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call